COMMEMORATING WORLD KIDNEY DAY, ETANA ENCOURAGES GREATER ACCESS TO ANEMIA THERAPY FOR CKD PATIENTS

Jakarta, March 11, 2026 – In commemoration of World Kidney Day, PT Etana Biotechnologies Indonesia (Etana) is encouraging greater access to anemia therapy for patients with chronic kidney disease (CKD) in Indonesia. This initiative reflects Etana’s commitment to supporting comprehensive kidney disease management while helping improve patients’ quality of life in a sustainable manner.

As part of anemia management in CKD patients, erythropoietin (EPO) therapy plays an important role in helping maintain hemoglobin levels. To support the availability of this therapy, Etana provides Renogen, a locally manufactured EPO product that has been used in healthcare services in accordance with medical standards and national clinical guidelines.

Roy Priadi, Director of the Renal & Cardio Business Unit at Etana, stated, “Chronic kidney disease not only affects organ function but also significantly impacts patients’ quality of life. Therefore, ensuring access to appropriate therapy is essential. Through local production, Etana aims to provide high-quality treatment that is more accessible and sustainable for patients in Indonesia.”

Chronic kidney disease has become an increasingly significant health challenge in Indonesia. Globally, around one in ten adults experiences kidney disorders, and a similar trend is occurring in Indonesia as the number of people living with diabetes and hypertension two major risk factors for kidney damage—continues to rise. This condition also places a considerable burden on the national healthcare system, as kidney disease treatment represents one of the largest expenditures within Indonesia’s National Health Insurance (JKN) program.

Etana also continues to promote collaboration with various stakeholders to strengthen kidney care services, including increasing public education, supporting healthcare professionals, and ensuring the availability of therapies that align with national clinical guidelines. In conjunction with World Kidney Day, Etana is collaborating with the Indonesian Society of Nephrology (PERNEFRI) to improve awareness of chronic kidney disease, particularly regarding the importance of early detection, prevention of disease progression, and comprehensive management in advanced stages, including dialysis and kidney transplantation.

Strengthening collaboration among the medical community, industry, and other stakeholders is essential to improving awareness and the management of chronic kidney disease in Indonesia.

Dr. dr. Pringgodigdo Nugroho, Sp.PD-KGH, Chairman of the Indonesian Society of Nephrology (PERNEFRI), stated “Strengthening early detection systems is a crucial foundation for slowing the progression of chronic kidney disease in Indonesia. Currently, many patients are still diagnosed at advanced stages, limiting opportunities to slow kidney damage. Through collaboration among stakeholders and support for therapeutic innovation, kidney disease management is expected to become more integrated and ultimately improve patients’ quality of life.”

“We believe that collaboration is key to expanding access to treatment. With the support of a strong healthcare ecosystem from education and therapy availability to strengthening local production we can collectively improve the quality of life of patients with chronic kidney disease in Indonesia,” Roy added.

At the same time, kidney care services in Indonesia still face several challenges. Many cases of chronic kidney disease are diagnosed only at advanced stages, making treatment more complex and requiring long-term, sustainable therapy. In addition, disparities in healthcare access across regions and the significant financial burden on the healthcare system also affect the management of this disease.

Through its capability to produce EPO locally, Etana aims to support a more stable supply of medicines while strengthening the self-reliance of Indonesia’s pharmaceutical industry, ensuring that the therapies needed by patients can be more widely available and sustainably accessible.

About Etana

Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility are able to produce biological therapy with halal certification from the Indonesian Ulama Council (MUI). Etana aspires to become the leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com